THERAPY DOSSIER · th-7a57a131dc54

Paeoniflorin

Nutraceutical · Monoterpene glycoside from Paeonia; no ChEMBL mechanism record.

Evidence & regulatory context

Mechanism: Monoterpene glycoside from Paeonia; no ChEMBL mechanism record.
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL4303209 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Peoniflorin
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02878863 ↗PHASE3withdrawn

Paeoniflorin + Hepatoprotective Drugs vs Hepatoprotective Drugs in Autoimmune Hepatitis

Hepatitis, Autoimmune

Enrolment: 0 · Results not recorded

NCT05973097 ↗NArecruiting

Paeoniflorin + Photodynamic Therapy for Oral Lichen Planus

Oral Lichen Planus

Enrolment: 156 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30627586 ↗2018Reported benefit

Neuroprotection by Paeoniflorin against Nuclear Factor Kappa B-Induced Neuroinflammation on Spinal Cord Injury.

RatSpinal cord injuryCompressionSprague-DawleyMale and femalen = 30 per group across sham, injury and paeoniflorin groups; t…Intraperitoneal20 mg/kg/dayStarted the day after surgery

Model: T9 laminectomy followed by spinal cord crush with a vascular clip at 15 g force for 1 min

Paeoniflorin improved hindlimb locomotor recovery at 7 and 14 days, reduced histopathological damage and neuronal loss, and suppressed NF-kappaB nuclear translocation with lower iNOS, COX-2, Nogo-A, Bax and cleaved caspase-3.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…